[VIEW] agent=Infection Prevention & Control (IPC) Director | scenario_id=112 | rounds=20

--- Round 0 ---
[R0.1] Infection Prevention & Control (IPC) Director (speak, public): To effectively reduce hospital-onset C. difficile infections across our 4-hospital system, I'd like to discuss our current cleaning performance, operational execution, and potential product changes. Let's start with our current state: we've seen a hospital-onset CDI rate of 9.8 per 10,000 patient-days against a goal of 6.0, and our UV marker removal rate is 71% across 18 units, short of our 85% target. Can you both share your perspectives on these metrics and any challenges you're facing?
[R0.2] Environmental Services (EVS) Operations Manager (speak, public): Our current cleaning performance shows a median terminal clean cycle time of 62 minutes per discharge, against a target of 55 minutes. We're also seeing 54% adherence to disinfectant dwell-time based on 80 timed audits, with a required contact time of 10 minutes. ATP surface testing on high-touch areas shows a 76% pass rate from 320 swabs, against a threshold of 250 RLU. Lastly, our EVS staff have completed 78% of the training for the updated enteric protocol, with a deadline of March 31, 2026. To improve our infection-control outcomes, could you clarify how you're measuring cleaning effectiveness and what specific outcomes we're targeting?
[R0.3] Supply Chain Contracting Director (speak, public): We've been using QuatClean Plus across all four hospitals, with an annual spend of $312,000. If we switch to sporicidal wipes, our monthly spend would increase by $28,000 at current usage levels. Our supplier has a capacity of 3,500 canisters per week and a lead time of 14 days. Can you help me understand the clinical drivers behind the proposed changes and whether we expect demand to remain stable throughout the remediation period?

--- Round 1 ---
[R1.1] Infection Prevention & Control (IPC) Director (speak, public): Our current metrics show a hospital-onset CDI rate of 9.8 per 10,000 patient-days, significantly higher than our goal of 6.0. The UV marker removal rate is 71%, below our target of 85%. To improve, we're considering switching to sporicidal disinfectants. EVS Operations Manager, can you share more about the operational feasibility of implementing this change, especially regarding staff training and adherence to the updated protocol? Supply Chain Contracting Director, can you provide insights on the procurement process and potential lead times for the new disinfectants?
[R1.2] Environmental Services (EVS) Operations Manager (speak, public): To implement sporicidal disinfectants effectively, we'll need to assess our current cleaning performance and identify areas for improvement. We've already started training our EVS staff on the updated enteric protocol, with 78% completion so far. However, we need to ensure that our staff are adequately trained on the new disinfectants and that we have a plan in place for monitoring adherence. I'd like to know more about the specific outcomes we're targeting with the switch to sporicidal disinfectants and how we'll measure success.
[R1.3] Supply Chain Contracting Director (speak, public): To better understand the operational feasibility and potential challenges, I'd like to know more about the specific outcomes we're targeting with the switch to sporicidal disinfectants and how we plan to measure success. Additionally, are there any specific concerns about demand stability throughout the remediation period that I should be aware of when shaping our sourcing and contracting approach?

--- Round 2 ---
[R2.1] Infection Prevention & Control (IPC) Director (speak, public): To address our current CDI rate of 9.8 per 10,000 patient-days and UV marker removal rate of 71%, we're considering switching to sporicidal disinfectants. EVS Operations Manager, can you share more about the operational feasibility of implementing this change, especially regarding staff training and adherence to the updated protocol? Supply Chain Contracting Director, can you provide insights on the procurement process and potential lead times for the new disinfectants?
[R2.2] Environmental Services (EVS) Operations Manager (speak, public): To effectively implement sporicidal disinfectants, we need clarity on the specific outcomes we're targeting and how we'll measure success. I'd like to understand how the switch aligns with our current CDI rate of 9.8 per 10,000 patient-days and UV marker removal rate of 71%. Additionally, can we discuss the budget impact and supply reliability for the new disinfectants to ensure we're making an informed decision?
[R2.3] Supply Chain Contracting Director (speak, public): To address the budget impact and supply reliability concerns for the new disinfectants, I can share that our supplier has a capacity of 3,500 canisters per week and a lead time of 14 days. This information should help us gauge the supply reliability. Regarding the budget, switching to sporicidal wipes would increase our monthly spend by $28,000 at current usage levels. Let's discuss how this fits into our overall plan and whether there are any specific concerns about demand stability throughout the remediation period.

--- Round 3 ---
[R3.1] Infection Prevention & Control (IPC) Director (speak, public): To effectively reduce our hospital-onset CDI rate of 9.8 per 10,000 patient-days, we need to focus on both cleaning effectiveness and operational execution. EVS Operations Manager, can you confirm if your team can meet the required disinfectant dwell-time and complete the training for sporicidal disinfectants by our target date? Supply Chain Contracting Director, can you provide an update on the procurement process for the new disinfectants and any potential contractual implications?
[R3.2] Environmental Services (EVS) Operations Manager (speak, public): To confirm our ability to meet the required disinfectant dwell-time and complete the training for sporicidal disinfectants, I'll need to assess our current operational capacity and potential challenges. Can you provide more details on the specific training requirements for the new disinfectants and any additional resources we might need? Additionally, I'd appreciate an update on how the procurement process is progressing and any potential contractual implications that could affect our implementation timeline.
[R3.3] Supply Chain Contracting Director (speak, public): To address the procurement process for the new disinfectants and potential contractual implications, I can confirm that our supplier has a capacity of 3,500 canisters per week and a lead time of 14 days. Switching to sporicidal wipes would increase our monthly spend by $28,000 at current usage levels. I'd like to understand more about the operational challenges you foresee in implementing the new disinfectants, particularly regarding staff training and adherence to the updated protocol. Are there any specific concerns about demand stability or potential hotspots that could impact our sourcing and contracting approach?

--- Round 4 ---
[R4.1] Infection Prevention & Control (IPC) Director (speak, public): To ensure we're on track with implementing sporicidal disinfectants, EVS Operations Manager, can you provide an update on your team's progress in training and adherence to the new protocol? Supply Chain Contracting Director, can you confirm if there are any contractual lock-in risks associated with switching to sporicidal wipes that we should consider in our 60-day remediation plan?
[R4.2] Environmental Services (EVS) Operations Manager (speak, public): To effectively implement sporicidal disinfectants within our 60-day remediation plan, I need to understand the specific outcomes we're targeting and how we'll measure success. I'd like to confirm if our current cleaning performance metrics, such as terminal clean cycle time and ATP surface testing, will be sufficient to gauge the effectiveness of the new disinfectants. Additionally, can we discuss any potential contractual implications or lock-in risks associated with switching to sporicidal wipes that could impact our implementation timeline?
[R4.3] Supply Chain Contracting Director (speak, private to=Infection Prevention & Control (IPC) Director): To address the contractual lock-in risks associated with switching to sporicidal wipes, I'll need to discuss this privately as it involves sensitive contract information. IPC Director, I'd like to follow up with you directly on this matter. In the meantime, I can share that our supplier has a capacity of 3,500 canisters per week and a lead time of 14 days, which should help with our implementation timeline. EVS Operations Manager, regarding your concerns about measuring success with the new disinfectants, we should consider tracking the same metrics you're currently using, such as terminal clean cycle time and ATP surface testing, to gauge effectiveness.

--- Round 5 ---
[R5.1] Infection Prevention & Control (IPC) Director (speak, public): To ensure we're on track with our 60-day remediation plan, let's summarize our current understanding. EVS Operations Manager, can you confirm if your team is on track to complete the training for sporicidal disinfectants and meet the required disinfectant dwell-time? Supply Chain Contracting Director, can you provide an update on the procurement process and any potential contractual implications?
[R5.2] Environmental Services (EVS) Operations Manager (speak, public): To effectively implement sporicidal disinfectants within our 60-day remediation plan, I'd like to confirm that we're aligning our efforts with the targeted infection-control outcomes. Can we discuss how the switch to sporicidal disinfectants will be measured for success, particularly in relation to our current CDI rate and UV marker removal rate? Additionally, I'd appreciate an update on the procurement process and any potential contractual implications that could affect our implementation timeline.
[R5.3] Supply Chain Contracting Director (speak, public): To align our efforts with the targeted infection-control outcomes, we need to ensure that our procurement process for sporicidal disinfectants is on track and that we're aware of any potential contractual implications. I've already shared that our supplier has a capacity of 3,500 canisters per week and a lead time of 14 days, which should support our implementation timeline. Switching to sporicidal wipes would increase our monthly spend by $28,000 at current usage levels. Let's confirm if there are any specific concerns about demand stability or potential hotspots that could impact our sourcing and contracting approach.

--- Round 6 ---
[R6.1] Infection Prevention & Control (IPC) Director (speak, public): To ensure we're on track with our 60-day remediation plan, let's summarize our current understanding. EVS Operations Manager, can you confirm if your team is on track to complete the training for sporicidal disinfectants and meet the required disinfectant dwell-time? Supply Chain Contracting Director, can you provide an update on the procurement process and any potential contractual implications?
[R6.2] Environmental Services (EVS) Operations Manager (speak, public): To confirm our alignment with the targeted infection-control outcomes, I'd like to summarize our current understanding. We've discussed implementing sporicidal disinfectants, with Supply Chain Contracting Director confirming a supplier capacity of 3,500 canisters per week and a lead time of 14 days. The budget impact is estimated at an additional $28,000 monthly spend. I've assessed our operational readiness, with 78% of EVS staff trained on the updated enteric protocol. To finalize our 60-day remediation plan, can we confirm the specific metrics we'll use to measure success and how we'll monitor progress?
[R6.3] Supply Chain Contracting Director (speak, public): To finalize our 60-day remediation plan, I've gathered that we're on track with the procurement process for sporicidal disinfectants, with a supplier capacity of 3,500 canisters per week and a lead time of 14 days. The budget impact is estimated at an additional $28,000 monthly spend. EVS Operations Manager, can you confirm if your team is on track to complete the training for sporicidal disinfectants and meet the required disinfectant dwell-time? IPC Director, are there any specific metrics or outcomes you're planning to use to measure the success of our remediation efforts?

--- Round 7 ---
[R7.1] Infection Prevention & Control (IPC) Director (speak, public): To finalize our 60-day remediation plan, let's summarize our key findings and next steps. EVS Operations Manager, you've assessed operational readiness and confirmed that 78% of EVS staff are trained on the updated enteric protocol. Supply Chain Contracting Director, you've secured a supplier with a capacity of 3,500 canisters per week and a lead time of 14 days, with an estimated additional $28,000 monthly spend for sporicidal wipes. To measure success, we'll track our hospital-onset CDI rate, UV marker removal rate, and ATP surface testing results. Let's confirm our alignment and next steps.
[R7.2] Environmental Services (EVS) Operations Manager (speak, public): To finalize our 60-day remediation plan, I confirm that we've assessed our operational readiness and are on track to complete the training for sporicidal disinfectants. We've achieved 78% completion on the updated enteric protocol training among our EVS staff. To measure success, we'll track our current cleaning performance metrics, including terminal clean cycle time, disinfectant dwell-time adherence, and ATP surface testing results. Let's confirm our alignment on the next steps and ensure we're meeting the targeted infection-control outcomes.
[R7.3] Supply Chain Contracting Director (leave, public): 

--- Round 8 ---
[R8.1] Infection Prevention & Control (IPC) Director (speak, public): To finalize our 60-day remediation plan, let's confirm our alignment on the next steps. We'll track our hospital-onset CDI rate, UV marker removal rate, and ATP surface testing results to measure success. EVS Operations Manager, please proceed with completing the training for sporicidal disinfectants and ensure adherence to the required disinfectant dwell-time. Supply Chain Contracting Director, please confirm the procurement process is on track and address any potential contractual implications. Let's reconvene in two weeks to review our progress.
[R8.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R8.3] Supply Chain Contracting Director (leave, public): 

--- Round 9 ---
[R9.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R9.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R9.3] Supply Chain Contracting Director (leave, public): 

--- Round 10 ---
[R10.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R10.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R10.3] Supply Chain Contracting Director (leave, public): 

--- Round 11 ---
[R11.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R11.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R11.3] Supply Chain Contracting Director (leave, public): 

--- Round 12 ---
[R12.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R12.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R12.3] Supply Chain Contracting Director (leave, public): 

--- Round 13 ---
[R13.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R13.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R13.3] Supply Chain Contracting Director (leave, public): 

--- Round 14 ---
[R14.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R14.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R14.3] Supply Chain Contracting Director (leave, public): 

--- Round 15 ---
[R15.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R15.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R15.3] Supply Chain Contracting Director (leave, public): 

--- Round 16 ---
[R16.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R16.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R16.3] Supply Chain Contracting Director (leave, public): 

--- Round 17 ---
[R17.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R17.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R17.3] Supply Chain Contracting Director (leave, public): 

--- Round 18 ---
[R18.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R18.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R18.3] Supply Chain Contracting Director (leave, public): 

--- Round 19 ---
[R19.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R19.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R19.3] Supply Chain Contracting Director (leave, public): 

